NeurologyOnline.net

Neurology Xagena

Search results for "Daclizumab HYP"

Daclizumab, a humanised monoclonal antibody, modulates interleukin-2 signalling by blocking the alpha subunit ( CD25 ) of the interleukin-2 receptor.Researchers have assessed whether Daclizumab high-y ...


In the SELECT trial, disease activity was reduced in patients with multiple sclerosis who received Daclizumab high-yield process ( HYP ) for 52 weeks. The primary aim of the SELECTION extension st ...


The full results from the phase 3 DECIDE clinical trial have shown a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis ( RRMS ) w ...